Stay updated on Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial

Sign up to get notified when there's something new on the Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The NIH transition announcement banner was removed from the top of the page, which otherwise remains a 403 Forbidden error.
    Difference
    1%
    Check dated 2026-11-09T03:18:46.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    The footer site revision changed from v3.7.2 to v3.8.0; the study page still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-02T02:44:13.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    A site-wide banner was added announcing NIH’s terminology transition and linking to updates and FAQs. The study record itself remains inaccessible behind a 403 error.
    Difference
    1%
    Check dated 2026-10-26T03:58:29.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.1 to v3.7.2 on the error page.
    Difference
    0.2%
    Check dated 2026-10-19T03:01:12.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov error page displays site revision v3.7.1 instead of v3.7.0.
    Difference
    0.2%
    Check dated 2026-10-12T02:37:54.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the previous study content. This indicates that access to the study record is blocked and users are presented with an error screen instead of study details.
    Difference
    17%
    Check dated 2026-09-21T00:43:35.000Z thumbnail image

Stay in the know with updates to Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial page.